Personalis, Inc. to Present at NeoAg Summit US 2019
21 11월 2019 - 10:00PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that the company will present at the
NeoAg Summit US 2019 in Boston on November 21st at 9:15 AM EST.
The presentation, entitled “ImmunoID NeXT: A Comprehensive
Platform for Improving Neoantigen Prediction, Tumor Escape
Mechanism Reporting, TME Assessment, and Tumor Heterogeneity
Profiling for Immuno-Oncology,” will provide an overview of
Personalis’ newly-launched cancer immunogenomics platform,
specifically highlighting innovative machine learning-based methods
for the comprehensive identification of neoantigens and the
detection of emerging and novel biomarkers of response and
resistance to immunotherapy.
ImmunoID NeXT™ is the first platform to enable comprehensive
analysis of both a tumor and its immune microenvironment from a
single sample. ImmunoID NeXT™ can be used to investigate the key
tumor- and immune-related areas of cancer biology, consolidating
multiple oncology biomarker assays into one and maximizing the
biological information that can be generated from a precious tumor
specimen.
The presentation will be delivered by Sean M. Boyle, PhD, Sr.
Director, Bioinformatics Applications for Personalis.
Personalis will also be exhibiting during the conference
(Exhibit #9). Representatives will be available to answer questions
about the company’s cancer immunogenomics capabilities.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191121005329/en/
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024